Cutaneous Anaplastic Large Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Cutaneous Anaplastic Large Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-13Clinical Trial Results: Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating Brentuximab Vedotin in combination with Lenalidomide for relapsed or refractory T-cell lymphoma including cutaneous…
-
CLINICAL_TRIALS trial_result · 2026-01-20Clinical Trial Update: SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) [Phase 2]
Phase 2 clinical trial update for brentuximab vedotin (SGN-35) in CD30-positive lymphoproliferative disorders, including primary cutaneous a…
-
CLINICAL_TRIALS trial_result · 2025-07-25Clinical Trial Update: Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma [Phase 2]
A Phase 2 study evaluating brentuximab vedotin in combination with lenalidomide for stage IB-IVB relapsed or refractory T-cell lymphoma has …
-
CLINICAL_TRIALS trial_result · 2018-03-16Clinical Trial Update: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) [Phase 3]
Phase 3 trial comparing Brentuximab Vedotin to physician's choice in CD30-positive cutaneous T-cell lymphoma completed with posted results.
-
CLINICAL_TRIALS trial_result · 2014-12-18Clinical Trial Update: Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma [Phase 2]
This clinical trial update reports results from a Phase 2 study of SGN-30 in patients with primary cutaneous anaplastic large cell lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-08-19FDA Approved: ADCETRIS — Supplemental Application (SEAGEN INC.)
The FDA approved a supplemental application for ADCETRIS (brentuximab vedotin) submitted by Seagen Inc.
-
CLINICAL_TRIALS withdrawal · 2010-04-26Clinical Trial Update: MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma [Phase 2]
This Phase 2 trial evaluating MDX-060 in relapsed or refractory anaplastic large cell lymphoma (systemic and primary cutaneous) has been wit…